Mural Oncology PLC Financials
Financial Health Signals
Mural Oncology PLC passes 0 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Mural Oncology PLC generates $1.00 in operating cash flow (-$128.5M OCF vs -$128.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Mural Oncology PLC (MURA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Mural Oncology PLC's EBITDA was -$134.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.4% from the prior year.
Mural Oncology PLC generated -$128.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 34.9% from the prior year.
Mural Oncology PLC reported -$128.5M in net income in fiscal year 2024. This represents an increase of 38.0% from the prior year.
Mural Oncology PLC earned $-7.58 per diluted share (EPS) in fiscal year 2024. This represents an increase of 39.0% from the prior year.
Mural Oncology PLC held $115.5M in cash against $0 in long-term debt as of fiscal year 2024.
Mural Oncology PLC had 17M shares outstanding in fiscal year 2024. This represents an increase of 2.4% from the prior year.
Mural Oncology PLC invested $110.7M in research and development in fiscal year 2024. This represents a decrease of 33.1% from the prior year.
Mural Oncology PLC invested $92K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 97.3% from the prior year.
MURA Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $23.3M-15.6% | $27.6M | N/A | $40.4M | N/A | $44.8M |
| SG&A Expenses | $8.3M+26.7% | $6.5M | N/A | $6.0M | N/A | $4.5M |
| Operating Income | -$4.0M+88.4% | -$34.1M | N/A | -$46.3M | N/A | -$49.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | N/A | $5.0M | N/A | $1.3M |
| Net Income | -$3.7M+88.3% | -$31.8M | N/A | -$51.3M | N/A | -$50.6M |
| EPS (Diluted) | $-0.21+88.8% | $-1.87 | N/A | $-3.07 | N/A | $-3.03 |
MURA Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Total Assets | $65.8M-61.2% | $169.4M-43.9% | $301.7M+899.1% | $30.2M-10.5% | $33.8M | N/A |
| Current Assets | $62.2M-59.4% | $152.9M-44.9% | $277.3M+5490.3% | $5.0M+3.0% | $4.8M | N/A |
| Cash & Equivalents | $58.9M-49.0% | $115.5M-57.4% | $270.9M | N/A | $0 | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.6M-63.4% | $28.9M-23.8% | $37.9M+2.2% | $37.1M-33.1% | $55.4M | N/A |
| Current Liabilities | $10.5M-59.8% | $26.2M-9.7% | $29.0M+9.9% | $26.4M-36.5% | $41.6M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $55.2M-60.7% | $140.5M-46.7% | $263.8M+3927.9% | -$6.9M+68.2% | -$21.7M-51.4% | -$14.3M |
| Retained Earnings | -$244.2M-53.2% | -$159.4M-416.5% | -$30.9M | N/A | $0 | N/A |
MURA Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.5M+41.8% | -$31.8M+25.6% | -$42.7M+15.3% | -$50.5M-33.2% | -$37.9M | N/A |
| Capital Expenditures | $0-100.0% | $23K-98.0% | $1.2M+1.0% | $1.2M+715.4% | $143K | N/A |
| Free Cash Flow | -$18.5M+41.9% | -$31.8M+27.6% | -$43.9M+15.0% | -$51.6M-35.8% | -$38.0M | N/A |
| Investing Cash Flow | $0-100.0% | $36.2M+3174.2% | -$1.2M-1.0% | -$1.2M-715.4% | -$143K | N/A |
| Financing Cash Flow | $0 | $0-100.0% | $315.0M+510.1% | $51.6M+35.8% | $38.0M | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A |
MURA Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -5.6%+10.0pp | -15.6% | N/A | -169.8% | N/A | N/A |
| Current Ratio | 5.90+0.1 | 5.84-3.7 | 9.56+9.4 | 0.19+0.1 | 0.12 | N/A |
| Debt-to-Equity | 0.19-0.0 | 0.21+0.1 | 0.14+5.5 | -5.38-2.8 | -2.56 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Mural Oncology PLC profitable?
No, Mural Oncology PLC (MURA) reported a net income of -$128.5M in fiscal year 2024.
What is Mural Oncology PLC's earnings per share (EPS)?
Mural Oncology PLC (MURA) reported diluted earnings per share of $-7.58 for fiscal year 2024. This represents a 39.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Mural Oncology PLC's EBITDA?
Mural Oncology PLC (MURA) had EBITDA of -$134.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Mural Oncology PLC's free cash flow?
Mural Oncology PLC (MURA) generated -$128.6M in free cash flow during fiscal year 2024. This represents a 34.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Mural Oncology PLC's operating cash flow?
Mural Oncology PLC (MURA) generated -$128.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Mural Oncology PLC's total assets?
Mural Oncology PLC (MURA) had $169.4M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Mural Oncology PLC's capital expenditures?
Mural Oncology PLC (MURA) invested $92K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Mural Oncology PLC spend on research and development?
Mural Oncology PLC (MURA) invested $110.7M in research and development during fiscal year 2024.
How many shares does Mural Oncology PLC have outstanding?
Mural Oncology PLC (MURA) had 17M shares outstanding as of fiscal year 2024.
What is Mural Oncology PLC's current ratio?
Mural Oncology PLC (MURA) had a current ratio of 5.84 as of fiscal year 2024, which is generally considered healthy.
What is Mural Oncology PLC's debt-to-equity ratio?
Mural Oncology PLC (MURA) had a debt-to-equity ratio of 0.21 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Mural Oncology PLC's return on assets (ROA)?
Mural Oncology PLC (MURA) had a return on assets of -75.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Mural Oncology PLC's cash runway?
Based on fiscal year 2024 data, Mural Oncology PLC (MURA) had $115.5M in cash against an annual operating cash burn of $128.5M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Mural Oncology PLC's Piotroski F-Score?
Mural Oncology PLC (MURA) has a Piotroski F-Score of 0 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Mural Oncology PLC's earnings high quality?
Mural Oncology PLC (MURA) has an earnings quality ratio of 1.00x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.